Immunotherapy for infectious diseases in haematological immunocompromise

Br J Haematol. 2017 May;177(3):348-356. doi: 10.1111/bjh.14595. Epub 2017 Mar 29.

Abstract

Opportunistic infections remain a major problem across a broad spectrum of immunocompromised haematological patient groups, with viruses, bacteria, fungi and protozoa all presenting significant challenges. Given the major difficulties in treating many of these infections with the currently available antimicrobial chemotherapeutic arsenal, and the rapid emergence of antimicrobial resistance amongst all of the microbial kingdoms, novel strategies that enable host control or elimination of infection are urgently required. Recently, major progress has been made in our understanding of host immunocompromise in the haematological patient. In addition, a wide range of novel immunomodulatory strategies for infectious diseases have been developed. Here we discuss the major and wide-ranging areas of progress that have been made for host-directed immunotherapies in the context of infectious diseases, with relevance to haematological immunocompromise.

Keywords: Infection; antibodies; cell therapy; cytokines; immunotherapy.

Publication types

  • Review

MeSH terms

  • Cell- and Tissue-Based Therapy / methods
  • Colony-Stimulating Factors / therapeutic use
  • Cytokines / therapeutic use
  • Hematologic Diseases / complications
  • Hematologic Diseases / immunology*
  • Hematologic Diseases / therapy
  • Humans
  • Immunocompromised Host*
  • Immunoglobulins / therapeutic use
  • Immunotherapy / methods*
  • Immunotherapy / trends
  • Opportunistic Infections / complications
  • Opportunistic Infections / immunology
  • Opportunistic Infections / therapy*
  • Probiotics / therapeutic use
  • Vaccines

Substances

  • Colony-Stimulating Factors
  • Cytokines
  • Immunoglobulins
  • Vaccines